0001798618 2025-12-16 2025-12-16 0001798618 1 2025-12-16 2025-12-16 0001798618 1 2025-12-16 2025-12-16 0001798618 2 2025-12-16 2025-12-16 iso4217:USD pure shares N-2 424B5 EX-FILING FEES 333-292201 0001798618 PIMCO Dynamic Income Opportunities Fund N/A false true false N-2 PIMCO Dynamic Income Opportunities Fund false Equity Common Shares of Beneficial Interest, $0.00001 par value per share true 500000000.00 0.0001381 69050.00 500000000.00 69050.00 0.00 21144.10 47905.90 The registration fee is calculated in accordance with Rule 457(o) under the Securities Act of 1933, as amended (the "Securities Act"), based on the proposed maximum aggregate offering price. true PIMCO Dynamic Income Opportunities Fund N-2 333-269645 2023-02-09 21144.10 Equity Common Shares of Beneficial Interest, $0.00001 par value per share 191870200.00 true PIMCO Dynamic Income Opportunities Fund N-2 333-269645 2023-02-09 55100.00 The registration fee is calculated in accordance with Rule 457(o) under the Securities Act of 1933, as amended (the "Securities Act"), based on the proposed maximum aggregate offering price PIMCO Dynamic Income Opportunities Fund (the "Fund") previously registered the offer and sale of its common shares having an aggregate offering price of up to $500,000,000, offered by means of a Rule 424(b)(5) prospectus supplement, filed February 9, 2023 (the "Prior Prospectus Supplement"), pursuant to the Registration Statement on Form N-2 (File No. 333-286525) filed on February 8, 2023. As of the date of this prospectus supplement, common shares having an aggregate offering price of up to $191,870,200 were not sold under the Prior Prospectus Supplement. Pursuant to Rule 457(p) under the Securities Act, an amount of $21,144.10 corresponding to the registration fee that was paid and remains unused with respect to securities that were previously registered pursuant to the Prior Prospectus Supplement and were not sold thereunder is offset against the registration fee due for this offering. The offering pursuant to the Prior Prospectus Supplement has terminated. Please refer to Footnote 2 above.